Filter by Last updated date SelectAfterBeforeFrom - To Date End Date This week This month Last week Last month Category HumanCorporateVeterinaryHerbal Topic MedicinesCOVID-19PharmacovigilanceVaccinesReferralsPaediatricsRare diseasesRegulatory and procedural guidanceClinical trialsAdvanced therapiesData on medicinesCompliance and inspectionsInnovationMedicine shortagesResearch and developmentBiosimilarsSMEAntimicrobial resistanceCorporateGovernanceBrexitQuality of medicinesGeneric and hybrid medicinesEarly accessMedicines for use outside the EUFeesProduct informationMedical devicesScientific adviceMaximum residue limitMpoxBiologicalsScientific guidelinesVeterinary limited marketsCompassionate usePRIMECareersMedication errorSpeechParallel distributionProcurement Diseases area Viral diseasesCancerImmune-system diseasesDiabetesNeurodegenerative diseasesCardiovascular diseasesHIV and AIDS Responsible body CHMP CVMP PRAC Management Board COMP PDCO CMDh HMPC CAT Patient safety information Patient safety Leave this field blank Filter Results (3876) Sort by Last update date (new to old)Last update date (old to new)A-ZZ-A Leave this field blank Public Statement on the risk of drug interactions with Hypericum perforatum (St John's Wort) and antiretroviral medicinal products 28 February 2000News Committee for Proprietary Medicinal Products (CPMP) 57th plenary meeting 21 February 2000Press release Public statement on Insuman Infusat 100-IU/ml solution for injection in cartridges of 3.15 ml (insulin human) - Risk of leakage during use 14 February 2000News Committee for veterinary medicinal products: 52nd meeting 10 February 2000Press releaseVeterinary Public Statement on Ziagen (Abacavir) - Important safety Information on Hypersensitivity Reactions and Respiratory Symptoms 24 January 2000News Committee for Proprietary Medicinal Products (CPMP) 56th plenary meeting 24 January 2000Press release 3rd meeting of the Committee for Orphan Medicinal Products 19 January 2000Press releaseHumanRare diseases Committee for veterinary medicinal products: 51st meeting 13 January 2000Press releaseVeterinary Public Statement on Rapilysin (Reteplase) - Incompatibility with Heparin and Precipitation following the Reconstitution - Important New Instructions for Use 23 December 1999News Committee for Proprietary Medicinal Products (CPMP) 55th plenary meeting 20 December 1999Press release 1 … 370 371 372 373 374 Page 374 of 388 375 376 377 378 … 388
Public Statement on the risk of drug interactions with Hypericum perforatum (St John's Wort) and antiretroviral medicinal products 28 February 2000News
Committee for Proprietary Medicinal Products (CPMP) 57th plenary meeting 21 February 2000Press release
Public statement on Insuman Infusat 100-IU/ml solution for injection in cartridges of 3.15 ml (insulin human) - Risk of leakage during use 14 February 2000News
Public Statement on Ziagen (Abacavir) - Important safety Information on Hypersensitivity Reactions and Respiratory Symptoms 24 January 2000News
Committee for Proprietary Medicinal Products (CPMP) 56th plenary meeting 24 January 2000Press release
3rd meeting of the Committee for Orphan Medicinal Products 19 January 2000Press releaseHumanRare diseases
Public Statement on Rapilysin (Reteplase) - Incompatibility with Heparin and Precipitation following the Reconstitution - Important New Instructions for Use 23 December 1999News
Committee for Proprietary Medicinal Products (CPMP) 55th plenary meeting 20 December 1999Press release